This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Investor enthusiasm and reaction to the Fed's interest rate decision carried over to health stocks Tuesday, refreshing numerous names -- some with and some without news.

One of the bigger gainers, Sangamo BioSciences (SGMO - Get Report), presented animal-study data that showed human CD4 T-cells can be made permanently resistant to HIV infection by treatment with zinc finger DNA-binding protein nucleases and preferentially survive and expand in mice after HIV infection. Shares added $1.40, or 11.7%, to $13.40.

Nektar Therapeutics (NKTR - Get Report) gained 57 cents, or 6.8%, to $8.93 after it said Tuesday that it created two new research units to drive its research initiatives under Nektar's PEGylation (use of a polymer to improve a drug's stability and ability to remain available in the body) and Pulmonary Business, which includes its inhaled antibiotic programs. The company said this will align its research activities with its strategic business objectives and allow for better decision-making and portfolio prioritization.

Nektar named Tim Riley vice president of its PEGylation research unit and John "Jay" Sisco as vice president of its pulmonary research unit. The company is a component of the Nasdaq biotechnology index, which was up 18.74, or 2.24%, to 843.51.

Elsewhere, Goldman Sachs upgraded Shire (SHPGY) to buy from neutral, adding it to its "conviction buy" list.

Shares slid last week following discussion that the company was having difficulty switching patients who were using Adderall XR (the Adderall patent is set to expire in early 2009) to its Vyvanse, which is protected until 2023. Goldman said the issues shouldn't be surprising given the limited period Vyvanse has been available in the U.S. and the fact that the school term began just recently. Shire added $2.44, or 3.5%, to $71.28.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIB $72.12 0.00%
NKTR $15.64 0.00%
SGMO $7.58 0.00%
AAPL $118.03 0.00%
FB $105.41 0.00%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs